Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 292

1.

An in vivo patient-derived model of endogenous IDH1-mutant glioma.

Luchman HA, Stechishin OD, Dang NH, Blough MD, Chesnelong C, Kelly JJ, Nguyen SA, Chan JA, Weljie AM, Cairncross JG, Weiss S.

Neuro Oncol. 2012 Feb;14(2):184-91. doi: 10.1093/neuonc/nor207. Epub 2011 Dec 13.

2.

Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation.

Lazovic J, Soto H, Piccioni D, Lou JR, Li S, Mirsadraei L, Yong W, Prins R, Liau LM, Ellingson BM, Cloughesy TF, Lai A, Pope WB.

Neuro Oncol. 2012 Dec;14(12):1465-72. doi: 10.1093/neuonc/nos258. Epub 2012 Oct 22.

3.

Hominoid-specific enzyme GLUD2 promotes growth of IDH1R132H glioma.

Chen R, Nishimura MC, Kharbanda S, Peale F, Deng Y, Daemen A, Forrest WF, Kwong M, Hedehus M, Hatzivassiliou G, Friedman LS, Phillips HS.

Proc Natl Acad Sci U S A. 2014 Sep 30;111(39):14217-22. doi: 10.1073/pnas.1409653111. Epub 2014 Sep 15.

4.

Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma.

Raghunathan A, Olar A, Vogel H, Parker JR, Coventry SC, Debski R, Albarracin CT, Aldape KD, Cahill DP 3rd, Powell SZ, Fuller GN.

Ann Diagn Pathol. 2012 Aug;16(4):255-9. doi: 10.1016/j.anndiagpath.2011.11.003. Epub 2012 Mar 23.

PMID:
22445362
5.

IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.

Zhang C, Moore LM, Li X, Yung WK, Zhang W.

Neuro Oncol. 2013 Sep;15(9):1114-26. doi: 10.1093/neuonc/not087. Epub 2013 Jul 21. Review.

6.

Metabolism of glioma and IDH1/IDH2 mutations.

Rossetto M, Ciccarino P, Boisselier B, Labussiere M, Sanson M.

Rev Neurol (Paris). 2011 Oct;167(10):699-703. doi: 10.1016/j.neurol.2011.08.002. Epub 2011 Aug 31. Review.

PMID:
21885076
7.

Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1R132H-Induced Metabolic Liabilities.

Waitkus MS, Pirozzi CJ, Moure CJ, Diplas BH, Hansen LJ, Carpenter AB, Yang R, Wang Z, Ingram BO, Karoly ED, Mohney RP, Spasojevic I, McLendon RE, Friedman HS, He Y, Bigner DD, Yan H.

Cancer Res. 2018 Jan 1;78(1):36-50. doi: 10.1158/0008-5472.CAN-17-1352. Epub 2017 Nov 2.

8.

Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.

Pope WB, Prins RM, Albert Thomas M, Nagarajan R, Yen KE, Bittinger MA, Salamon N, Chou AP, Yong WH, Soto H, Wilson N, Driggers E, Jang HG, Su SM, Schenkein DP, Lai A, Cloughesy TF, Kornblum HI, Wu H, Fantin VR, Liau LM.

J Neurooncol. 2012 Mar;107(1):197-205. doi: 10.1007/s11060-011-0737-8. Epub 2011 Oct 21.

9.

IDH1 R132H mutation generates a distinct phospholipid metabolite profile in glioma.

Esmaeili M, Hamans BC, Navis AC, van Horssen R, Bathen TF, Gribbestad IS, Leenders WP, Heerschap A.

Cancer Res. 2014 Sep 1;74(17):4898-907. doi: 10.1158/0008-5472.CAN-14-0008. Epub 2014 Jul 8.

10.

Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.

Turcan S, Fabius AW, Borodovsky A, Pedraza A, Brennan C, Huse J, Viale A, Riggins GJ, Chan TA.

Oncotarget. 2013 Oct;4(10):1729-36.

11.

D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma.

Pusch S, Schweizer L, Beck AC, Lehmler JM, Weissert S, Balss J, Miller AK, von Deimling A.

Acta Neuropathol Commun. 2014 Feb 14;2:19. doi: 10.1186/2051-5960-2-19.

12.

IDH1 mutations in gliomas: when an enzyme loses its grip.

Frezza C, Tennant DA, Gottlieb E.

Cancer Cell. 2010 Jan 19;17(1):7-9. doi: 10.1016/j.ccr.2009.12.031.

13.

5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft.

Borodovsky A, Salmasi V, Turcan S, Fabius AW, Baia GS, Eberhart CG, Weingart JD, Gallia GL, Baylin SB, Chan TA, Riggins GJ.

Oncotarget. 2013 Oct;4(10):1737-47.

14.

Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis.

Johannessen TA, Mukherjee J, Viswanath P, Ohba S, Ronen SM, Bjerkvig R, Pieper RO.

Mol Cancer Res. 2016 Oct;14(10):976-983. Epub 2016 Jul 18.

15.

Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis.

Ohba S, Hirose Y.

Neurol Med Chir (Tokyo). 2016;56(4):170-9. doi: 10.2176/nmc.ra.2015-0322. Epub 2016 Mar 10. Review.

16.

Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.

Wakimoto H, Tanaka S, Curry WT, Loebel F, Zhao D, Tateishi K, Chen J, Klofas LK, Lelic N, Kim JC, Dias-Santagata D, Ellisen LW, Borger DR, Fendt SM, Vander Heiden MG, Batchelor TT, Iafrate AJ, Cahill DP, Chi AS.

Clin Cancer Res. 2014 Jun 1;20(11):2898-909. doi: 10.1158/1078-0432.CCR-13-3052. Epub 2014 Apr 8.

17.

Characterizing invading glioma cells based on IDH1-R132H and Ki-67 immunofluorescence.

Sabit H, Nakada M, Furuta T, Watanabe T, Hayashi Y, Sato H, Kato Y, Hamada J.

Brain Tumor Pathol. 2014 Oct;31(4):242-6. doi: 10.1007/s10014-013-0172-y. Epub 2014 Jan 3.

PMID:
24384677
18.

Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation.

Ohka F, Ito M, Ranjit M, Senga T, Motomura A, Motomura K, Saito K, Kato K, Kato Y, Wakabayashi T, Soga T, Natsume A.

Tumour Biol. 2014 Jun;35(6):5911-20. doi: 10.1007/s13277-014-1784-5. Epub 2014 Mar 5.

PMID:
24590270
19.

IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo.

Bralten LB, Kloosterhof NK, Balvers R, Sacchetti A, Lapre L, Lamfers M, Leenstra S, de Jonge H, Kros JM, Jansen EE, Struys EA, Jakobs C, Salomons GS, Diks SH, Peppelenbosch M, Kremer A, Hoogenraad CC, Smitt PA, French PJ.

Ann Neurol. 2011 Mar;69(3):455-63. doi: 10.1002/ana.22390.

PMID:
21446021
20.

Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and α-KG.

Navis AC, Niclou SP, Fack F, Stieber D, van Lith S, Verrijp K, Wright A, Stauber J, Tops B, Otte-Holler I, Wevers RA, van Rooij A, Pusch S, von Deimling A, Tigchelaar W, van Noorden CJ, Wesseling P, Leenders WP.

Acta Neuropathol Commun. 2013 May 29;1:18. doi: 10.1186/2051-5960-1-18.

Supplemental Content

Support Center